Summary - CMMB - NASDAQ - Weiss Ratings

D

Chemomab Therapeutics Ltd. CMMB

$3.42 -$0.0558-1.60% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$3.32 - $10.20

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Chemomab Therapeutics Ltd ADR trading halted, news pending

8/25/2025 - TipRanks Financial Blog

Chemomab Therapeutics Ltd - ADR trading halted, news pending

8/25/2025 - The Fly

Chemomab Therapeutics Announces ADS Ratio Change Effective August 26, 2025

8/22/2025 - TipRanks Financial Blog

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Short Interest Update

8/22/2025 - Ticker Report

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

8/21/2025 - GuruFocus

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference ...

8/21/2025 - GuruFocus

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

8/21/2025 - Globe Newswire

Roth MKM Remains a Buy on Chemomab Therapeutics (CMMB)

8/19/2025 - TipRanks Financial Blog

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate ...

8/14/2025 - GuruFocus

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

8/14/2025 - GuruFocus

Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year

8/14/2025 - The Fly

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

8/14/2025 - Globe Newswire

Chemomab Therapeutics management to meet with Maxim

8/8/2025 - The Fly

Chemomab Therapeutics management to meet with Maxim

8/7/2025 - The Fly

Chemomab Therapeutics management to meet with Maxim

7/31/2025 - The Fly

Chemomab Therapeutics Enters Sales Agreement with LifeSci Capital

7/25/2025 - TipRanks Financial Blog

Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug

6/30/2025 - The Fly

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

6/30/2025 - Globe Newswire

Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)

6/12/2025 - TipRanks Financial Blog

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

6/11/2025 - Globe Newswire

KURA Stock Rises More Than 15% This Past Week: Here's Why

6/6/2025 - Zacks Investment Research

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

6/6/2025 - Zacks Investment Research

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

6/3/2025 - Globe Newswire

MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

6/2/2025 - Zacks Investment Research

Short Interest in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Drops By 37.2%

6/1/2025 - Ticker Report

Income Statement

Total Revenue (TTM)

--

EBITDA (TTM)

--

EBIT (TTM)

--

Net Income (TTM)

--

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

--

Cash from Investing (TTM)

--

Cash from Financing (TTM)

--

Net Change in Cash (TTM)

--

Filings

Filing Date

Thursday, August 14, 2025

Period Date

Monday, June 30, 2025

Next Filing

Week of Nov 10 and 14 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

--

52-week Low

Aug 25, 2025 - $3.32

52-week High

Sep 03, 2024 - $10.20

Valuation

Market Cap

$72.00M - Micro Cap

Enterprise Value

Price/Sales (TTM)

--

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

www.chemomab.com

Phone Number

972 77 331 0156

Address

Building 7
Tel Aviv, 6158002

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United... more